01—Abstract
Summary
Summary of the 8-K filed December 17, 2024. Cited figures are marked; the original filing is the authoritative source.
On December 16, 2024, CVS Health announced the early results, election of early settlement, and pricing of its cash tender offer (the "Maximum Tender Offer") for a basket of its senior notes and certain Aetna Inc.-issued senior notes.
The offer is capped at a Maximum Tender Offer Amount of $1,774,423,242.62a (excluding accrued interest). Holders who tendered by the December 13, 2024 Early Tender Date, which has passed with withdrawal rights expired, will receive the Total Consideration including a $30 per $1,000 Early Tender Payment, plus accrued interest, with settlement expected December 18, 2024. The tender was oversubscribed.
Because aggregate purchase prices of notes tendered by the early deadline exceeded the cap, CVS expects to accept the Maximum Tender Offer Amount subject to proration, and no notes tendered after the Early Tender Date are expected to be accepted. Notes in the 2031 (2.125%b and 1.875%), 2048 Aetna 4.500%-type series and certain others fell into lower acceptance priority levels, with the 2.125% 2031, 1.875% 2031, 5.050% 2048, 4.500% Aetna 2042 and 1.750% 2030 series receiving 0% proration, meaning those tendered holders will not have notes purchased. The 4.125% 2040 and 2.700% 2040 series were largely accepted, with the 4.125% 2040 series at a 57.5% approximate proration factor.
For investors, this filing is primarily a liability management action: CVS is retiring a portion of its outstanding debt through a capped repurchase, with the pricing set by a fixed spread over the relevant Treasury benchmark. The filing does not disclose the funding source or the financial impact on CVS's leverage, earnings, or cash position, and the document itself is a routine tender-offer disclosure with no new operating or guidance information.
02—Key points
Key Highlights
- Maximum Tender Offer capped at $1,774,423,242.62 (excluding accrued interest) across nine series of CVS Health and Aetna Inc. senior notes.
- Early Tender Date of December 13, 2024 passed; tendered notes can no longer be withdrawn.
- Early Tender Payment of $30 per $1,000 principal amount is included in the Total Consideration for notes tendered by the early deadline.
- Offer was oversubscribed, so proration applies; 2031, 2048 (5.050%), 2042 Aetna (4.500%) and 2030 series show 0% expected proration.
- Early Settlement Date set for December 18, 2024, after which no further notes are expected to be purchased under the offer.
- Pricing is based on fixed spreads (+87 to +156 bps) over U.S. Treasury reference securities as of 10:00 a.m. ET on December 16, 2024.
- Filing contains no disclosure of funding sources, financial impact, or operating or guidance changes.
03—Questions
Frequently Asked Questions
What is the purpose of the Maximum Tender Offer?
The offer is a cash tender for a capped aggregate amount of CVS Health and Aetna senior notes, allowing CVS to repurchase outstanding debt from holders at a price set by a fixed spread over Treasury benchmarks. The filing does not state the strategic rationale beyond the repurchase itself.
Will my notes be purchased if I tendered them?
It depends on the series and acceptance priority. Because the offer was oversubscribed, notes are accepted in priority order subject to proration. Series such as the 2.125% and 1.875% 2031 notes, 5.050% 2048 notes, 4.500% Aetna 2042 notes and 1.750% 2030 notes are expected to have 0% proration, meaning tendered notes in those series will not be purchased and will be returned.
What will tendering holders receive?
Holders whose notes were tendered by the Early Tender Date and accepted will receive the Total Consideration per $1,000 principal amount, which includes the $30 Early Tender Payment, plus accrued and unpaid interest up to the Early Settlement Date of December 18, 2024. Notes tendered after the Early Tender Date would receive only the Tender Offer Consideration, which excludes the early payment, but no such notes are expected to be accepted.
Can tenders still be withdrawn or will additional notes be bought?
The withdrawal deadline of 5:00 p.m. New York time on December 13, 2024 has passed, so tendered notes cannot be withdrawn. CVS does not expect to purchase additional notes after the December 18, 2024 Early Settlement Date, though it reserves the right to amend, extend or terminate the offer.
How does this transaction affect CVS's financial position?
The filing does not disclose the funding source, total cash outlay beyond the capped amount, or effect on leverage, interest expense, or earnings. Investors would need to review CVS's subsequent periodic reports or financing disclosures for those details.
04—Continue